Hos kræftpatienter i kemoterapi var blodtransfusion nødvendig hos færre patienter i Aranesp- gruppen end i placebogruppen.
In cancer patients receiving chemotherapy, fewer patients treated with Aranesp needed a blood transfusion compared with those given placebo.